GLP-1 CollectivePolicy tracker
What is changing,
and what it means for you.
Bills, lawsuits and coverage decisions, written for patients rather than lawyers. You do not need an account to read any of it.
Latest update · October 12, 2026
Eli Lilly v. Willow Health Services pending in Ninth Circuit
The docket does not say what the dispute is about, and its latest action is dated March 5, 2026.
- Federal lawsuit against Novo Nordisk is pending in Pennsylvania October 11, 2026
- Amgen registers Phase 3 trial against semaglutide October 10, 2026
- UBT251 triple agonist shows weight reduction in phase 2 trial October 9, 2026
- A pill version of GLP-1 drugs just matched a standard diabetes drug October 8, 2026
- Five new semaglutide trials in Egypt focus on bariatric surgery October 7, 2026
What your state Medicaid covers
Every state Medicaid programme covers GLP-1 medications for type 2 diabetes. Whether it covers the same medications for weight is decided state by state, and states have been changing their minds in both directions. The map is on the page that carries the rest of the government coverage rules, so that it and the Medicare answer sit together.
Every bill and lawsuit, by state
The map is coverage. If you want the legislation itself, GLP1Laws tracks every bill, lawsuit and coverage decision state by state and is free to read.